Stocks and Investing
Stocks and Investing
Tue, June 4, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gregory Renza Maintained (AGIO) at Buy with Increased Target to $53 on, Jun 4th, 2024
Gregory Renza of RBC Capital, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Buy with Increased Target from $44 to $53 on, Jun 4th, 2024.
Gregory has made no other calls on AGIO in the last 4 months.
There are 2 other peers that have a rating on AGIO. Out of the 2 peers that are also analyzing AGIO, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $30 on, Friday, February 23rd, 2024
This is the rating of the analyst that currently disagrees with Gregory
- Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy on, Tuesday, April 9th, 2024
Contributing Sources